[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639916":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":44,"id":58,"slug":10,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":10,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Herlev and Gentofte Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients referred for work-up suspected of lung cancer",null,"Patients are enrolled when these are referred to the Pulmonology Department suspected of lung cancer.",[13],"Diagnostic Test: Blood tests",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Blood tests","Standard blood tests, Novel protein tumor markers specifically targeting lung cancer, Epigenetic smoking marker (AHRR methylation), Combined fragmentome, mutational and methylome analysis of cell-free tumor DNA",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Søren Egstrand, MD, PhD","CONTACT","0045 21682147","soeren.egstrand@regionh.dk",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Gentofte Hospital","RECRUITING","Gentofte Municipality","Denmark",{"type":33,"coordinates":34},"Point",[35,36],12.54601,55.74903,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Søren Egstrand","MD, PhD",[45,48,50,52,54,56],{"name":46,"class":47},"NEYE Foundation","UNKNOWN",{"name":49,"class":47},"Direktør Michael Hermann Nielsens mindelegat, afd B",{"name":51,"class":47},"Toyota Foundation Denmark",{"name":53,"class":47},"Grosserer L. F. Foghts Fond Denmark",{"name":55,"class":6},"Beckett Foundation",{"name":57,"class":47},"P. A. Messerschmidt & hustrus Fond","100639916",false,"NCT07623473","Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE","Inclusion Criteria:\n\n* Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit\n* Having signed informed consent\n\nExclusion Criteria:\n\n* Active cancer, excluding non-melanoma skin cancer\n* Comorbidities that exclude the patient from clinical follow-up and final diagnosis",true,"ALL",{"count":68,"type":69},1800,"ESTIMATED","OBSERVATIONAL","The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.\n\nEach blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.",[73,74],"Lung Cancer (Diagnosis)","Nodule, Solitary Pulmonary",[76,77,78,79,80],"Biomarkers","Lung nodule","Fragmentomics","Methylome","Cell-free DNA","2026-05-29",{"date":83,"type":84},"2026-06-03","ACTUAL",{"date":86,"type":84},"2024-05-22",{"date":88,"type":69},"2028-02-01",{"name":5,"class":6},1]